A Phase 3 interventional study of GH and Placebo in Spinal Cord Injury, sponsored by Hospital Nacional de Parapléjicos de Toledo. Completed at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-05-31.
Sponsored by Hospital Nacional de Parapléjicos de Toledo · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Spinal Cord Injuries with a site in Spain — 12 open to participants now, 13 under way, 1 of them phase 3. Spinal Cord Injuries · Spain.
Among the 59 studies in Spinal Cord Injuries with a site in Spain, this one is the 9th largest by enrollment of the 55 interventional ones that give a count, is one of 2 that started in 2011, is the only one in phase 3, and was the 4th registered.
2,028 studies on the registry are indexed under Spinal Cord Injuries; 540 are open to participants now.
Browse Spinal Cord Injuries studies →12 of the 59 studies in Spinal Cord Injuries with a site in Spain are open now. Recruiting first, the newest first:
ABLE Human Motion S.L. · Sites in Spain
Ages up to 17
ABLE Human Motion S.L. · Sites in Spain
Ages 18–70
Technophage, SA · Sites in Spain
Ages 18–65
MarsiBionics · Sites in Spain
Ages 3–14
Institut Guttmann · Sites in Spain
Ages 18–99
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 376 Spinal Cord Injuries studies recruiting now, 167 (44%) set no upper age limit and 158 (42%) stop at 75 or younger; 41 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 14 · Phase 3 2 · Phase 4 2
First in 2005; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is above the median of 24 across 1,635 interventional studies indexed under Spinal Cord Injuries.
Median enrollment 30 across the 55 interventional studies, 51 across the 4 observational. Of the 40 that completed or were terminated, 5 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 59 have an industry lead sponsor. The 10 most frequent:
Hospital Nacional de Parapléjicos de Toledo is the lead sponsor of 6 studies on the registry; none are open to participants now.
Hospital Nacional de Parapléjicos de Toledo has 6 studies filed under Spinal Cord Injuries — fewer than ten, so there is no comparison to draw.
4 of the studies in Spinal Cord Injuries with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06677229Technophage, SAPhase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury | 2026-12 |
| NCT07745712ABLE Human Motion S.L.Clinical Investigation to Validate the Safety and Performance of the ABLE Kids Device in Pediatric Patients With Neurological Gait Disorders in a Clinical Setting | 2026-12-31 |
| NCT05142943University of ValenciaEffectiveness of Virtual Bodily Illusion Intervention in Upper Limb Motor Function in People With Incomplete Spinal Cord Injury. | 2026-12-31 |
| NCT07036107ABLE Human Motion S.L.A Trial on the Clinical and Socioeconomic Impact of Wearable Exoskeletons for Spinal Cord Injury Rehabilitation in the Spanish Healthcare System | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies in Spinal Cord Injuries with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Objectives: To evaluate the efficacy and safety of one year treatment based on daily doses of exogenous growth hormone (GH) in patients with traumatic spinal cord injury. The first six months the pharmacological treatment will be associated to rehabilitation treatment.
The main hypothesis is that GH can improve motor function of patients with traumatic spinal cord injury below the lesion level. The hypothesis is based on possible effects of GH at muscle and synaptic level. GH can also promote axonal growth and regeneration.
Design: Clinical trial placebo-controlled, double-blind intervention with blind evaluation by third parties and blinding in the analysis of data (triple-blind design).
Duration of intervention and monitoring: 364 days.
Primary outcome measures. Changes of the American Spinal Injury Association (ASIA) scale (motor score)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administration of a daily dose of GH (0.4mg)for 1 year
Drug: GH
Administration of a daily dose of placebo for 1 year
Drug: Placebo
Administration of a subcutaneously injected daily dose of GH (0.4mg)for 1 year
Also known as: Genotonorm
Administration of a subcutaneously injected daily dose of placebo for 1 year
Also known as: Provided by the Genotonorm producer (Pfizer)
Motor Score of the American Spinal Injury Association (ASIA) scale
Motor score of the ASIA scale reports the strenght of 10 key muscles in each body side (5 key muscles in upper limb and 5 key muscles in lower limb). The strenght is rated between 0 and 5 (Medical Research Council-MRC scale). The ASIA motor score range is between 0 and 100 (normal).
Time frame: 12 months
ASIA
ASIA grades
Time frame: 12 months
ASIA sensory score
ASIA sensory score
Time frame: 12 months
Spasticity
Penn scale and Ashworth scale
Time frame: Baseline, 15 days, 6 months, 12 months
Pain
Visual analogic scale (VAS)
Time frame: Baseline, 15 days, 6 months, 12 months
Independence Measures and Quality of life
Spinal Cord Indipendence Measures (SCIM) and the Quality of Life Questionnaire (EQ 5D)
Time frame: 12 months
Neurophysiological Measures
Motor Evoked Potentials, Somatosensory Evoked Potentials, Motor Neurography
Time frame: 6 months and 12 months
Safety
Recording of any adverse event, full blood and urine examination
Time frame: 15, 30, 60, 90, 120, 150, 180, 360 days
Ran from Apr 2011 to primary completion in Nov 2015, 55 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone
Hospital Nacional de Parapléjicos de Toledo